Antibody-conjugated liposomes targeting ASTL have demonstrated significant potential in ovarian cancer research. By targeting the methylated ASTL antigen, these liposomes can effectively enhance the targeting and efficacy of drugs. They not only increase drug accumulation in the tumor microenvironment but also reduce toxicity to normal cells. Overall, antibody-conjugated liposomes targeting ASTL offer new ideas and strategies for targeted therapy in ovarian cancer.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
AGTO-L044S | anti-ASTL immunotoxin D-8 (Fab)-Sap | Cytotoxicity assay, Functional assay |
There are currently no Customer reviews or questions for VS-1024-FY210. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.